Urology San Antonio Trials

Urology San Antonio	Welcome, Profile Billing Logout

33 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Saltzstein, Daniel R

NCT06604442: Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy

Recruiting

Flotufolastat (18F), piflufolastat (18F)

Blue Earth Diagnostics, Aixial Group

Prostate Cancer

05/25

VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Terminated

105

VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga

Veru Inc.

Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer

05/23

BOND3, NCT04452591: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Recruiting

190

Japan, US, RoW

Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside, DDM

CG Oncology, Inc.

Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer

12/27

12/29

SABRE, NCT05407311: 64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer

Completed

64Cu-SAR-BBN

Clarity Pharmaceuticals Ltd

Biochemical Recurrence of Malignant Neoplasm of Prostate

05/24

NCT03945162: Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

Recruiting

125

Canada, US

Ruvidar® (TLD-1433) Bladder infusion and PDT

Theralase® Technologies Inc., University Health Network, Toronto, Pharma eMarket

Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG

06/25

12/25

VERU-100, NCT04843319: To Determine an Effective Dose of for the Treatment of Advanced Prostate Cancer

Terminated

1b/2

VERU-100

Veru Inc.

Advanced Prostate Adenocarcinoma

01/23

COBRA, NCT05249127: 64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer

Completed

1/2

64Cu-SAR-bisPSMA

Clarity Pharmaceuticals Ltd

Biochemical Recurrence of Malignant Neoplasm of Prostate

08/23

CELLO-1, NCT04179864 / 2019-003649-14: A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer

	Data from CELLO-1 trial for CRPC at SUO 2022
	Dec 2022 - Dec 2022: Data from CELLO-1 trial for CRPC at SUO 2022
	Safety data from P1b portion of P1b/2 trial in combination with enzalutamide or with abiraterone/prednisone for CRPC at ESMO 2021
	Sep 2021 - Sep 2021: Safety data from P1b portion of P1b/2 trial in combination with enzalutamide or with abiraterone/prednisone for CRPC at ESMO 2021

Terminated

1/2

102

Europe, US

Tazemetostat, EPZ-6438, E7438, IPN60200, Abiraterone/prednisone, Zytiga, Enzalutamide, Xtandi

Epizyme, Inc.

Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer

11/24

NCT06655064: Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging Evaluations

Recruiting

N/A

500

None- Observational

Telix Pharmaceuticals (Innovations) Pty Limited, Specialty Networks Research.

Prostate Cancer (Adenocarcinoma)

12/26

12/27

Cantrill, Christopher

AEROLITH, NCT04563039: Acoustic Enhancer Research on Laser Lithotripsy

Completed

N/A

196

Ureteroscopy Laser Lithotripsy (URS-LL) with Acoustic Enhancer, Standard Ureteroscopic Laser Lithotripsy

Avvio Medical

Urinary Stones

07/23

CLEAR, NCT04338776: Comparing UroLift Experience Against Rezūm

Active, not recruiting

N/A

120

Europe, US

UroLift, Rezum

NeoTract, Inc.

Benign Prostatic Hyperplasia

05/25

12/25

Shoup, Pam

VITALIZE, NCT04920617 / 2021-003712-27: DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recruiting

102

Europe, Canada, US, RoW

DPX-Survivac, maveropepimut-S, Pembrolizumab, MK-3475, Keytruda, CPA, Intermittent, low-dose cyclophosphamide, Procytox, Cytoxan

ImmunoVaccine Technologies, Inc. (IMV Inc.), Merck Sharp & Dohme LLC

Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma

10/24

04/25

NCT05319028: Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Terminated

Mivavotinib, CB-659

Calithera Biosciences, Inc

Non-GCB/ABC Diffuse Large B-Cell Lymphoma, With and Without MyD88 and/or CD79B Mutations

02/23

REVERCE II, NCT04117945: Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer

Active, not recruiting

Cetuximab, Cetuximab Biosimilar CDP-1, Cetuximab Biosimilar CMAB009, Cetuximab Biosimilar KL 140, Chimeric Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225, Chimeric Monoclonal Antibody C225, Erbitux, IMC-C225, Irinotecan, Panitumumab, ABX-EGF, ABX-EGF Monoclonal Antibody, ABX-EGF, Clone E7.6.3, MoAb ABX-EGF, Monoclonal Antibody ABX-EGF, Vectibix, Regorafenib, BAY 73-4506, Stivarga

Academic and Community Cancer Research United, National Cancer Institute (NCI)

BRAF V600E Negative, KRAS Gene Mutation Negative, Locally Advanced Unresectable Colorectal Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, NRAS Gene Mutation Negative, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8

09/23

03/25

PRL-02-1001, NCT04729114: A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Recruiting

174

PRL-02 injection, prednisone, dexamethasone, enzalutamide

Astellas Pharma Global Development, Inc.

Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer

08/25

05/29

NCT06126003: Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer.

Terminated

N/A

Observation

BioCorteX Inc, Tempus AI

Breast Cancer

07/24

NCT05234177: Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays

Recruiting

N/A

300

Observation

Tempus AI

Colorectal Cancer

02/27

02/29

Salinas, Kethsaly

NCT03850795: HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Terminated

104

Europe, Canada, US, RoW

HC-1119, Enzalutamide

Hinova Pharmaceuticals USA, Inc.

Prostate Cancer Metastatic, Castration-resistant Prostate Cancer

06/24

NCT03945162: Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

Recruiting

125

Canada, US

Ruvidar® (TLD-1433) Bladder infusion and PDT

Theralase® Technologies Inc., University Health Network, Toronto, Pharma eMarket

Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG

06/25

12/25

Hernandez, Manuel R

NCT05478174: Efficacy and Safety of HSK3486 Compared to Propofol for Adults Undergoing Elective Surgery With General Anesthesia

Completed

400

HSK3486, Propofol, Diprivan

Haisco-USA Pharmaceuticals, Inc.

General Anesthesia

11/23

AEROLITH, NCT04563039: Acoustic Enhancer Research on Laser Lithotripsy

Completed

N/A

196

Ureteroscopy Laser Lithotripsy (URS-LL) with Acoustic Enhancer, Standard Ureteroscopic Laser Lithotripsy

Avvio Medical

Urinary Stones

07/23

NCT06090331: 89Zr-DFO-girentuximab Expanded Access Program (EAP)

Available

N/A

89Zr-DFO-girentuximab

Telix Pharmaceuticals (Innovations) Pty Limited

Clear Cell Renal Cell Carcinoma

NCT05250908: INTIBIA Pivotal Study

Active, not recruiting

N/A

208

Europe, US

INTIBIA Therapeutic, INTIBIA Non-Therapeutic

Coloplast A/S

Urinary Incontinence, Urge, Urinary Bladder, Overactive, Urinary Bladder Diseases, Urologic Diseases, Lower Urinary Tract Symptoms, Urological Manifestations

06/25

06/26

NCT06655064: Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging Evaluations

Recruiting

N/A

500

None- Observational

Telix Pharmaceuticals (Innovations) Pty Limited, Specialty Networks Research.

Prostate Cancer (Adenocarcinoma)

12/26

12/27

Meissner, Kurt

PURSUIT, NCT04720352: Prospective US Radiofrequency SUI Trial

Recruiting

N/A

390

Active treatment, Sham

Viveve Inc.

Urinary Incontinence, Stress

12/22

Salas, Sandra

NCT03945162: Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

Recruiting

125

Canada, US

Ruvidar® (TLD-1433) Bladder infusion and PDT

Theralase® Technologies Inc., University Health Network, Toronto, Pharma eMarket

Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG

06/25

12/25

VERU-100, NCT04843319: To Determine an Effective Dose of for the Treatment of Advanced Prostate Cancer

Terminated

1b/2

VERU-100

Veru Inc.

Advanced Prostate Adenocarcinoma

01/23

PURSUIT, NCT04720352: Prospective US Radiofrequency SUI Trial

Recruiting

N/A

390

Active treatment, Sham

Viveve Inc.

Urinary Incontinence, Stress

12/22

Cerda, Jose De La

NCT05478174: Efficacy and Safety of HSK3486 Compared to Propofol for Adults Undergoing Elective Surgery With General Anesthesia

Completed

400

HSK3486, Propofol, Diprivan

Haisco-USA Pharmaceuticals, Inc.

General Anesthesia

11/23

CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting

900

Europe, Canada, Japan, US, RoW

Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib

Eli Lilly and Company

Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6

02/24

10/27

PRL-02-1001, NCT04729114: A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Recruiting

174

PRL-02 injection, prednisone, dexamethasone, enzalutamide

Astellas Pharma Global Development, Inc.

Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer

08/25

05/29

NCT05508568: A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer

Recruiting

N/A

650

ADXBLADDER

Arquer Diagnostics Ltd

Bladder Cancer

01/23

04/23

Kuntz, Nicholas

NCT06655064: Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging Evaluations

Recruiting

N/A

500

None- Observational

Telix Pharmaceuticals (Innovations) Pty Limited, Specialty Networks Research.

Prostate Cancer (Adenocarcinoma)

12/26

12/27

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Saltzstein, Daniel R

Recruiting

Flotufolastat (18F), piflufolastat (18F)

Blue Earth Diagnostics, Aixial Group

Prostate Cancer

05/25

VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Terminated

105

VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga

Veru Inc.

Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer

05/23

BOND3, NCT04452591: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Recruiting

190

Japan, US, RoW

Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside, DDM

CG Oncology, Inc.

Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer

12/27

12/29

SABRE, NCT05407311: 64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer

Completed

64Cu-SAR-BBN

Clarity Pharmaceuticals Ltd

Biochemical Recurrence of Malignant Neoplasm of Prostate

05/24

NCT03945162: Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

Recruiting

125

Canada, US

Ruvidar® (TLD-1433) Bladder infusion and PDT

Theralase® Technologies Inc., University Health Network, Toronto, Pharma eMarket

Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG

06/25

12/25

VERU-100, NCT04843319: To Determine an Effective Dose of for the Treatment of Advanced Prostate Cancer

Terminated

1b/2

VERU-100

Veru Inc.

Advanced Prostate Adenocarcinoma

01/23

COBRA, NCT05249127: 64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer

Completed

1/2

64Cu-SAR-bisPSMA

Clarity Pharmaceuticals Ltd

Biochemical Recurrence of Malignant Neoplasm of Prostate

08/23

CELLO-1, NCT04179864 / 2019-003649-14: A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer

	Data from CELLO-1 trial for CRPC at SUO 2022
	Dec 2022 - Dec 2022: Data from CELLO-1 trial for CRPC at SUO 2022
	Safety data from P1b portion of P1b/2 trial in combination with enzalutamide or with abiraterone/prednisone for CRPC at ESMO 2021
	Sep 2021 - Sep 2021: Safety data from P1b portion of P1b/2 trial in combination with enzalutamide or with abiraterone/prednisone for CRPC at ESMO 2021

Terminated

1/2

102

Europe, US

Tazemetostat, EPZ-6438, E7438, IPN60200, Abiraterone/prednisone, Zytiga, Enzalutamide, Xtandi

Epizyme, Inc.

Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer

11/24

NCT06655064: Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging Evaluations

Recruiting

N/A

500

None- Observational

Telix Pharmaceuticals (Innovations) Pty Limited, Specialty Networks Research.

Prostate Cancer (Adenocarcinoma)

12/26

12/27

Cantrill, Christopher

AEROLITH, NCT04563039: Acoustic Enhancer Research on Laser Lithotripsy

Completed

N/A

196

Ureteroscopy Laser Lithotripsy (URS-LL) with Acoustic Enhancer, Standard Ureteroscopic Laser Lithotripsy

Avvio Medical

Urinary Stones

07/23

CLEAR, NCT04338776: Comparing UroLift Experience Against Rezūm

Active, not recruiting

N/A

120

Europe, US

UroLift, Rezum

NeoTract, Inc.

Benign Prostatic Hyperplasia

05/25

12/25

Shoup, Pam

VITALIZE, NCT04920617 / 2021-003712-27: DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recruiting

102

Europe, Canada, US, RoW

DPX-Survivac, maveropepimut-S, Pembrolizumab, MK-3475, Keytruda, CPA, Intermittent, low-dose cyclophosphamide, Procytox, Cytoxan

ImmunoVaccine Technologies, Inc. (IMV Inc.), Merck Sharp & Dohme LLC

Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma

10/24

04/25

NCT05319028: Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Terminated

Mivavotinib, CB-659

Calithera Biosciences, Inc

Non-GCB/ABC Diffuse Large B-Cell Lymphoma, With and Without MyD88 and/or CD79B Mutations

02/23

REVERCE II, NCT04117945: Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer

Active, not recruiting

Academic and Community Cancer Research United, National Cancer Institute (NCI)

09/23

03/25

PRL-02-1001, NCT04729114: A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Recruiting

174

PRL-02 injection, prednisone, dexamethasone, enzalutamide

Astellas Pharma Global Development, Inc.

Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer

08/25

05/29

NCT06126003: Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer.

Terminated

N/A

Observation

BioCorteX Inc, Tempus AI

Breast Cancer

07/24

NCT05234177: Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays

Recruiting

N/A

300

Observation

Tempus AI

Colorectal Cancer

02/27

02/29

Salinas, Kethsaly

NCT03850795: HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Terminated

104

Europe, Canada, US, RoW

HC-1119, Enzalutamide

Hinova Pharmaceuticals USA, Inc.

Prostate Cancer Metastatic, Castration-resistant Prostate Cancer

06/24

NCT03945162: Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

Recruiting

125

Canada, US

Ruvidar® (TLD-1433) Bladder infusion and PDT

Theralase® Technologies Inc., University Health Network, Toronto, Pharma eMarket

Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG

06/25

12/25

Hernandez, Manuel R

NCT05478174: Efficacy and Safety of HSK3486 Compared to Propofol for Adults Undergoing Elective Surgery With General Anesthesia

Completed

400

HSK3486, Propofol, Diprivan

Haisco-USA Pharmaceuticals, Inc.

General Anesthesia

11/23

AEROLITH, NCT04563039: Acoustic Enhancer Research on Laser Lithotripsy

Completed

N/A

196

Ureteroscopy Laser Lithotripsy (URS-LL) with Acoustic Enhancer, Standard Ureteroscopic Laser Lithotripsy

Avvio Medical

Urinary Stones

07/23

NCT06090331: 89Zr-DFO-girentuximab Expanded Access Program (EAP)

Available

N/A

89Zr-DFO-girentuximab

Telix Pharmaceuticals (Innovations) Pty Limited

Clear Cell Renal Cell Carcinoma

NCT05250908: INTIBIA Pivotal Study

Active, not recruiting

N/A

208

Europe, US

INTIBIA Therapeutic, INTIBIA Non-Therapeutic

Coloplast A/S

Urinary Incontinence, Urge, Urinary Bladder, Overactive, Urinary Bladder Diseases, Urologic Diseases, Lower Urinary Tract Symptoms, Urological Manifestations

06/25

06/26

NCT06655064: Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging Evaluations

Recruiting

N/A

500

None- Observational

Telix Pharmaceuticals (Innovations) Pty Limited, Specialty Networks Research.

Prostate Cancer (Adenocarcinoma)

12/26

12/27

Meissner, Kurt

PURSUIT, NCT04720352: Prospective US Radiofrequency SUI Trial

Recruiting

N/A

390

Active treatment, Sham

Viveve Inc.

Urinary Incontinence, Stress

12/22

Salas, Sandra

NCT03945162: Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

Recruiting

125

Canada, US

Ruvidar® (TLD-1433) Bladder infusion and PDT

Theralase® Technologies Inc., University Health Network, Toronto, Pharma eMarket

Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG

06/25

12/25

VERU-100, NCT04843319: To Determine an Effective Dose of for the Treatment of Advanced Prostate Cancer

Terminated

1b/2

VERU-100

Veru Inc.

Advanced Prostate Adenocarcinoma

01/23

PURSUIT, NCT04720352: Prospective US Radiofrequency SUI Trial

Recruiting

N/A

390

Active treatment, Sham

Viveve Inc.

Urinary Incontinence, Stress

12/22

Cerda, Jose De La

NCT05478174: Efficacy and Safety of HSK3486 Compared to Propofol for Adults Undergoing Elective Surgery With General Anesthesia

Completed

400

HSK3486, Propofol, Diprivan

Haisco-USA Pharmaceuticals, Inc.

General Anesthesia

11/23

Active, not recruiting

900

Europe, Canada, Japan, US, RoW

Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib

Eli Lilly and Company

02/24

10/27

PRL-02-1001, NCT04729114: A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Recruiting

174

PRL-02 injection, prednisone, dexamethasone, enzalutamide

Astellas Pharma Global Development, Inc.

Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer

08/25

05/29

NCT05508568: A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer

Recruiting

N/A

650

ADXBLADDER

Arquer Diagnostics Ltd

Bladder Cancer

01/23

04/23

Kuntz, Nicholas

NCT06655064: Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging Evaluations

Recruiting

N/A

500

None- Observational

Telix Pharmaceuticals (Innovations) Pty Limited, Specialty Networks Research.

Prostate Cancer (Adenocarcinoma)

12/26

12/27

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites